Investors
- Stock Information
- News Releases
- Corporate Governance
- SEC Filings
- Annual Reports
- Financial Reports
- Event Calendar
- Presentations
- Non-GAAP Measures
- FAQ
- Information Request
- Analyst Coverage
For Pharmaceuticals
spin-off information,
click here.
News Release
 View printer-friendly version |
| << Back |
| Covidien Receives FDA Clearance for its Mallinckrodt(TM) TaperGuard(TM) Evac Endotracheal Tube |
| BOULDER, Colo., Sep 30, 2009 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products
and recognized innovator in mechanical ventilation and respiratory care
devices, today announced that it has received 510(k) clearance from the
U.S. Food and Drug Administration (FDA) to market its Mallinckrodt(TM)
TaperGuard(TM) Evac endotracheal tube. The TaperGuard endotracheal tube
reduces leakage past the cuff by at least 81%, compared with the
Mallinckrodt Hi-Lo(TM) endotracheal tube1, potentially reducing
the risk of postsurgical complications that may be caused by aspiration
of fluids into the lungs.
Although complications from pulmonary aspiration are rare, the consequences can be severe.2 Overall, the incidence of aspiration in adults is 1 in 3,000 anesthetics3, with a mortality rate of between 8% and 10%.4 High-volume, low-pressure (HVLP) cuffs were developed in the 1970s to reduce the risk of aspiration; however, fluid leakage past the cuff with conventional HVLP cuffs remains prevalent and is well-documented.5,6,7 Recent market research demonstrates limited clinical knowledge among physicians about the sealing performance of traditional HVLP endotracheal tube cuffs.8 "The FDA 510(k) clearance of the TaperGuard line of endotracheal tubes provides Covidien with an opportunity to further educate physicians about the risks and consequences associated with intraoperative leakage of secretions past inflated endotracheal tube cuffs," said Roger Mecca, M.D., Vice President, Medical Affairs, Respiratory and Monitoring Solutions, Covidien. "The possibility of postoperative complications related to unobserved aspiration past the cuff during general anesthesia is likely unappreciated, so enhancing awareness of this potential issue is timely." "The TaperGuard endotracheal tubes offer significant advantages for anesthesiologists, surgeons and their patients," said Jim Willett, General Manager and Vice President, Airway and Ventilation, Covidien. "This FDA 510(k) clearance means more physicians will gain awareness of this innovative product and incorporate its use into their procedures, confirming Covidien's mission to provide solutions designed to improve patient safety, medical efficacy and healthcare efficiency." About Covidien Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2008 revenue of $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. 1 510 (k) clearance letter. 2 Nagelhout, et al. Aspiration prophylaxis: Is it time for changes in our practice? AANA Journal. 2003; l71(4). 3 Rawlinson, E. Pulmonary aspiration. Anesthesia and Intensive Care Medicine 2007: 8(9); 365-367. 4 Benington, et al. Pulmonary aspiration. Anesthesia and Intensive Care Medicine. 2007; 8(9): 368. 5 Oikkonen M, Aromaa U. Leakage of fluid around low-pressure tracheal tube cuffs. Anaesthesia. 1997; 52: 567-569. 6 Young JP. Leakage of fluid past the tracheal tube cuff in a bench top model. British Journal of Anaesthesia. 1997; 78:557-562. 7 Lucangelo U, et al. Effect of positive expiratory pressure and type of tracheal cuff on the incidence of aspiration in mechanically ventilated patients in an intensive care unit. Critical Care Medicine. 2008; 36(1): 1-5. 8 Internal document. Market research performed by a 3rd party vendor. Conjoint Analysis.
SOURCE: Covidien Covidien |